Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gonadotropin-releasing hormone receptor antagonist |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L02BX07
|
| gptkbp:brand |
gptkb:Orgovyx
gptkb:Relumina |
| gptkbp:CASNumber |
737789-87-6
|
| gptkbp:chemicalFormula |
C29H27F2N7O5
|
| gptkbp:developer |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Myovant_Sciences |
| gptkbp:eliminationHalfLife |
36-65 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Relugolix
|
| gptkbp:KEGGID |
D10813
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
suppresses production of testosterone and estrogen
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
602.6 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
CHEMBL2103887
46216313 DB15181 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
increased risk of blood clots hot flashes |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
prostate cancer
endometriosis uterine fibroids |
| gptkbp:bfsParent |
gptkb:Myovant_Sciences
gptkb:ROIV |
| gptkbp:bfsLayer |
6
|